FINDLIFE PHARMACEUTICAL
⚠️ High Risk
FEI: 3032257312 • Surat • INDIA
High Risk
FDA Import Risk Assessment
This firm has a significant history of FDA import refusals with notable violations.
Statistics
Score Breakdown
How is this score calculated?
Proprietary Algorithm
- 40% Violation Severity — AI-assessed (1-10)
- 30% Refusal Volume — Logarithmic scale
- 20% Recency — Decays over 5 years
- 10% Frequency — Refusals per year
© ImportRefusal.com Original Analysis
Violation Summary
UNAPPROVED
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
Refusal History
| Date | Product | Violations | Division |
|---|---|---|---|
| 6/2/2025 | 61LDA12WARFARIN POTASSIUM (ANTI-COAGULANT) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/2/2025 | 66MDA64TRIFLUOPERAZINE HCL (TRANQUILIZER) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/2/2025 | 66SDA28NITROGLYCERIN (TAB) (VASODILATOR) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/2/2025 | 60NDA99ANDROGEN, N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 6/2/2025 | 62GDA99ANTI-INFLAMMATORY N.E.C. | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/23/2025 | 66MDA67TRIFLUPROMAZINE HCL (TRANQUILIZER) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/23/2025 | 62ODA49NIMODIPINE (ANTI-HYPERTENSIVE - PART II) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/23/2025 | 61TDA12METOCLOPRAMIDE HCL (ANTI-EMETIC/NAUSEANT) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/23/2025 | 62IDR15CYCLOPHOSPHAMIDE (ANTI-NEOPLASTIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/23/2025 | 62VDJ29IMIQUIMOD (ANTI-VIRAL) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/23/2025 | 62JDA18SELEGILINE HYDROCHLORIDE (ANTI-PARKINSONIAN) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/23/2025 | 62IDA15CYCLOPHOSPHAMIDE (ANTI-NEOPLASTIC) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
| 4/23/2025 | 66MDA32FLUPHENAZINE HCL (TRANQUILIZER) | 75UNAPPROVED | Division of Southeast Imports (DSEI) |
Frequently Asked Questions
What is FINDLIFE PHARMACEUTICAL's FDA import refusal history?
FINDLIFE PHARMACEUTICAL (FEI: 3032257312) has 13 FDA import refusal record(s) in our database, spanning from 4/23/2025 to 6/2/2025.
What is an FEI number?
FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. FINDLIFE PHARMACEUTICAL's FEI number is 3032257312.
What types of violations has FINDLIFE PHARMACEUTICAL received?
FINDLIFE PHARMACEUTICAL has been cited for 1 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.
Where does this information about FINDLIFE PHARMACEUTICAL come from?
All FDA import refusal data for FINDLIFE PHARMACEUTICAL is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.
Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.